Antidepressant pediatric risk re-examined
Executive Summary
An article in the April 18 issue of the Journal of the American Medical Association finds the "benefits of antidepressants [for pediatric use] appear to be much greater than risks from suicidal ideation, suicide attempt across indications." The meta-analysis by Jeffrey Bridge, Ohio State University, et al. finds antidepressant efficacy to be strongest for non-obsessive compulsive disorder anxiety disorders, intermediate for OCD and "more modest" for major depressive disorder. FDA recently extended the boxed suicidality warning for antidepressants to all patients under the age of 25 (1"The Pink Sheet" Jan. 1, 2007, p. 17)...
You may also be interested in...
More evidence of increasing suicide rate
A study in the American Journal of Psychiatry concludes that suicide rates in children and adolescents in the United States and the Netherlands are increasing. The study suggests that the rise may be associated with the decline of antidepressant prescriptions, which occurred after warnings linked the drugs to higher suicide risk in children, according to the study led by Robert Gibbons, University of Illinois at Chicago. "The data available from the CDC on U.S. suicide rates at the time of the study (through 2004) revealed that there was already a 14 percent increase in child and adolescent suicide rates from 2003 to 2004," the largest rise since 1979, the study states. Other recent research had similar findings, such as an April 2007 report in the Journal of the American Medical Association showing the benefits of antidepressants outweigh the risk of suicide in pediatrics (1"The Pink Sheet" April 23, 2007, In Brief)...
Impact of Antidepressant Black Box Juggled By Advisory Committee, FDA
The addition of new, positive data on adult suicidality to antidepressant labeling could be an opportunity to offset the negative impact the "black box" warning on pediatric suicidality has had on antidepressant use, according to members of FDA's Psychopharmacologic Drugs Advisory Committee
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.